Rapid engineering of soluble T cell receptors for enhanced affinity via a high-throughput yeast-based platform
Time: 9:20 am
day: Conference Day Two
Details:
• Soluble T cell receptor (TCR)-based CD3 bispecific therapeutics can co-opt T cell function to eradicate virally infected and cancerous cells via peptide-HLA (pHLA) recognition.
• Native TCRs require extensive affinity maturation for efficacy in clinically validated CD3 bispecific formats, posing a significant barrier to the development of soluble TCR-based therapeutics.
• Adimab has developed a high-throughput yeast-based platform to rapidly generate and characterize TCR variants with substantially improved affinities and functional potencies while retaining target specificity.
